Trial Profile
A study to demonstrate the efficacy of GSK Biologicals' influenza vaccine (Fluarix) administered intramuscularly in adults.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza A virus infections; Influenza B virus infections; Influenza virus infections
- Focus Therapeutic Use
- Sponsors GSK
- 15 Dec 2009 Results were published in the Journal of Infectious Diseases.
- 25 Oct 2008 Primary endpoint 'vaccine protective efficacy' has been met.
- 08 May 2008 Status changed from in progress to completed.